restrictions'
The European Medicines Agency has recommended changes to the use of
metoclopramide to reduce the risk of neurological side effects.
The review of metoclopramide, carried out at the request of the French medicines
regulatory agency, confirmed the well-known risks of neurological effects
including:
extrapyramidal disorders
involuntary movement disorders that may include muscle spasms
tardive dyskinesia
It was noted that [...]
You may view the latest post at
http://www.prescriber.org.uk/
No hay comentarios:
Publicar un comentario